In Vitro Models of Liver and Pancreatic Cancer

July 13, 2016 updated by: Dr. Kourosh Saeb-Parsy, Cambridge University Hospitals NHS Foundation Trust

A Study Designed to Develop in Vitro Models of Liver, Biliary and Pancreatic Cancer for the Investigation of Tumour Biology and Potential Therapies

The primary objective is to develop an in vitro model of cancer for laboratory study using liver, biliary and pancreatic cancer tissue. The secondary objective is to study the genetic and cellular biology of cancer of the liver, biliary tract and the pancreas. As well the investigators hope to compare molecular and cellular biology of cancer cells with normal cells as well as potentially test the efficacy of current and future anti-cancer therapies.

Samples will be collected from tissue that has been resected as part of the treatment for a patient diagnosed with liver, bile duct or pancreas cancer.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Genetic: Organoid in vitro culture

Study Type

Observational

Enrollment (Anticipated)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

United Kingdom
- - Cambridge, United Kingdom, CB2 0QQ
    - Recruiting
    - Addenbrooke's Hospital
    - Contact:
      
      Andrew Bradley, PhD, FRCS
      
      Phone Number: (3)36976 (7)62001
      
      Email: jab52@cam.ac.uk

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients who are undergoing surgical resenctions of liver, biliary or pancreas cancers that are able to give informed consent

Description

Inclusion Criteria:

All adult patients undergoing surgical resections for liver, biliary or pancreas cancers that are able to give informed consent.

Exclusion Criteria:

Patients aged <18 or those who are unable to give informed consent.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months. Time Frame: 3 years	3 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Proportion of tumour-derived organoids that are genetically identical to the source tumour. Time Frame: 3 years	3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cambridge University Hospitals NHS Foundation Trust

Collaborators

The Gurdon Institute

Ann McLaren Laboratory of Regenerative Medicine

Investigators

Principal Investigator: Kourosh Saeb-Parsy, PhD, FRCS, Cambridge Univeristy Hospitals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2015

Primary Completion (Anticipated)

September 1, 2018

Study Registration Dates

First Submitted

April 30, 2015

First Submitted That Met QC Criteria

May 4, 2015

First Posted (Estimate)

May 7, 2015

Study Record Updates

Last Update Posted (Estimate)

July 14, 2016

Last Update Submitted That Met QC Criteria

July 13, 2016

Last Verified

July 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

A093484

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.